These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 33100177)

  • 1. Brentuximab vedotin in real life, a seven year experience in patients with refractory/relapsed CD30+ T cell lymphoma.
    Oberic L; Delzor F; Protin C; Perriat S; Laurent C; Grand A; Canonge JM; Borel C; Gauthier M; Ysebaert L; Puisset F
    J Oncol Pharm Pract; 2021 Oct; 27(7):1730-1735. PubMed ID: 33100177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma.
    Shea L; Mehta-Shah N
    Curr Hematol Malig Rep; 2020 Feb; 15(1):9-19. PubMed ID: 32016790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of ifosfamide, carboplatin and etoposide in combination with brentuximab vedotin or romidepsin based on CD30 positivity in relapsed/refractory peripheral T-cell lymphoma.
    Gentille C; Sarfraz H; Joshi J; Randhawa J; Shah S; Pingali SR
    Cancer Rep (Hoboken); 2022 Jul; 5(7):e1581. PubMed ID: 35263030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of ALCL and other CD30+ peripheral T-cell lymphomas with a focus on Brentuximab vedotin.
    Nizamuddin I; Galvez C; Pro B
    Semin Hematol; 2021 Apr; 58(2):85-94. PubMed ID: 33906726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Short-Term Efficacy and Safety of Brentuximab Vedotin Plus Cyclophosphamide, Epirubicin and Prednisone in Untreated PTCL: A Real-World, Retrospective Study.
    Feng X; Guo W; Wang Y; Li J; Zhao Y; Qu L; Yan X; Li J; Guo Q; Young KH; Bai O
    Adv Ther; 2022 Jan; 39(1):532-543. PubMed ID: 34797505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.
    Fanale MA; Horwitz SM; Forero-Torres A; Bartlett NL; Advani RH; Pro B; Chen RW; Davies A; Illidge T; Huebner D; Kennedy DA; Shustov AR
    J Clin Oncol; 2014 Oct; 32(28):3137-43. PubMed ID: 25135998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.
    Narayan R; Blonquist TM; Emadi A; Hasserjian RP; Burke M; Lescinskas C; Neuberg DS; Brunner AM; Hobbs G; Hock H; McAfee SL; Chen YB; Attar E; Graubert TA; Bertoli C; Moran JA; Bergeron MK; Foster JE; Ramos AY; Som TT; Vartanian MK; Story JL; McGregor K; Macrae M; Behnan T; Wey MC; Rae J; Preffer FI; Lesho P; Duong VH; Mann ML; Ballen KK; Connolly C; Amrein PC; Fathi AT
    Cancer; 2020 Mar; 126(6):1264-1273. PubMed ID: 31860140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA Approval Summary: Brentuximab Vedotin in First-Line Treatment of Peripheral T-Cell Lymphoma.
    Richardson NC; Kasamon YL; Chen H; de Claro RA; Ye J; Blumenthal GM; Farrell AT; Pazdur R
    Oncologist; 2019 May; 24(5):e180-e187. PubMed ID: 30914464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas.
    Wagner SM; Melchardt T; Egle A; Magnes T; Skrabs C; Staber P; Simonitsch-Klupp I; Panny M; Lehner B; Greil R; Keil F; Jäger U; Sillaber C
    Eur J Haematol; 2020 Mar; 104(3):251-258. PubMed ID: 31838747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of patients with relapsed or refractory anaplastic large cell lymphoma who have failed brentuximab vedotin.
    Chihara D; Wong S; Feldman T; Fanale MA; Sanchez L; Connors JM; Savage KJ; Oki Y
    Hematol Oncol; 2019 Feb; 37(1):35-38. PubMed ID: 30209819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of brentuximab-vedotin and ifosfamide, carboplatin, etoposide in relapsed/refractory peripheral T-cell lymphoma.
    Van de Wyngaert Z; Coppo P; Cervera P; Fabiani B; Lemonnier MP; Corre E; Marjanovic Z; Aoudjhane M; Mohty M; Duléry R
    Eur J Haematol; 2021 Apr; 106(4):467-472. PubMed ID: 33320379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-CD30 antibody-drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives.
    Prince HM; Hutchings M; Domingo-Domenech E; Eichenauer DA; Advani R
    Ann Hematol; 2023 Jan; 102(1):13-29. PubMed ID: 36512081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma.
    Jagadeesh D; Horwitz S; Bartlett NL; Kim Y; Jacobsen E; Duvic M; Little M; Trepicchio W; Fenton K; Onsum M; Lisano J; Advani R
    Oncologist; 2022 Oct; 27(10):864-873. PubMed ID: 35948003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brentuximab Vedotin Retreatment in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma or Peripheral T-Cell Lymphoma: A Retrospective United States Claims Analysis.
    Sano D; Liu N; Knowles S; MacEwan JP; Wang S; Wogen J; Yu KS; Lee ST
    Curr Oncol; 2024 May; 31(5):2598-2609. PubMed ID: 38785476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brentuximab vedotin in the treatment of CD30+ PTCL.
    Barta SK; Gong JZ; Porcu P
    Blood; 2019 Dec; 134(26):2339-2345. PubMed ID: 31697814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of or decrease in CD30 expression in four patients with anaplastic large cell lymphoma after brentuximab vedotin-containing therapy.
    Kaimi Y; Takahashi Y; Taniguchi H; Ochi T; Makino H; Makita S; Iwaki N; Fukuhara S; Munakata W; Ogawa C; Izutsu K; Maeshima AM
    Virchows Arch; 2024 Mar; 484(3):465-473. PubMed ID: 38349387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.
    Merli M; Ferrario A; Maffioli M; Olivares C; Stasia A; Arcaini L; Passamonti F
    Expert Rev Hematol; 2016 Aug; 9(8):767-80. PubMed ID: 27416486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin.
    Oregel KZ; Everett E; Zhang X; Nagaraj G
    Expert Rev Anticancer Ther; 2016; 16(3):279-83. PubMed ID: 26809026
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment strategies and outcome in relapsed peripheral T-cell lymphoma: results from the Netherlands Cancer Registry.
    Brink M; Huisman F; Meeuwes FO; van der Poel MWM; Kersten MJ; Wondergem M; Böhmer L; Woei-A-Jin FJSH; Visser O; Oostvogels R; Jansen PM; Diepstra A; Snijders TJF; Huls G; Vermaat JSP; Plattel WJ; Nijland M
    Blood Adv; 2024 Jul; 8(14):3619-3628. PubMed ID: 38739705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brentuximab vedotin use in pediatric anaplastic large cell lymphoma.
    Agrusa JE; Egress ER; Lowe EJ
    Front Immunol; 2023; 14():1203471. PubMed ID: 37275877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.